MA55280A - Formulation solide de modulateur d'assemblage de capside - Google Patents

Formulation solide de modulateur d'assemblage de capside

Info

Publication number
MA55280A
MA55280A MA055280A MA55280A MA55280A MA 55280 A MA55280 A MA 55280A MA 055280 A MA055280 A MA 055280A MA 55280 A MA55280 A MA 55280A MA 55280 A MA55280 A MA 55280A
Authority
MA
Morocco
Prior art keywords
solid formulation
assembly modulator
capside
capside assembly
modulator
Prior art date
Application number
MA055280A
Other languages
English (en)
French (fr)
Inventor
Michaël Bertil S Anné
Claire Elisabeth Balmain
Maria Jansens
Oliver Lenz
Abhishek Singh
Jan Snoeys
Dycke Frederic Anne R Van
Joris Jozef Vandenbossche
Dominique Josiane W Verstraete
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2019/000231 external-priority patent/WO2019175657A1/en
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA55280A publication Critical patent/MA55280A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA055280A 2019-03-13 2020-03-13 Formulation solide de modulateur d'assemblage de capside MA55280A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/IB2019/000231 WO2019175657A1 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
US16/352,754 US10973801B2 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
EP2019056348 2019-03-13
EP19197566 2019-09-16

Publications (1)

Publication Number Publication Date
MA55280A true MA55280A (fr) 2022-01-19

Family

ID=72427202

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055280A MA55280A (fr) 2019-03-13 2020-03-13 Formulation solide de modulateur d'assemblage de capside

Country Status (16)

Country Link
EP (1) EP3937928A1 (de)
JP (1) JP2022524819A (de)
KR (1) KR20210137484A (de)
CN (1) CN113557016A (de)
AU (1) AU2020235442A1 (de)
BR (1) BR112021017525A2 (de)
CA (1) CA3132095A1 (de)
CR (1) CR20210481A (de)
EC (1) ECSP21067052A (de)
IL (1) IL286209A (de)
JO (1) JOP20210250A1 (de)
MA (1) MA55280A (de)
MX (1) MX2021011030A (de)
PE (1) PE20212107A1 (de)
SG (1) SG11202109710QA (de)
WO (1) WO2020183020A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017248828A1 (en) 2016-04-15 2018-11-01 Janssen Sciences Ireland Uc Combinations and methods comprising a capsid assembly inhibitor
CN111867582A (zh) * 2018-03-14 2020-10-30 爱尔兰詹森科学公司 衣壳组装调节剂给药方案

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
CN111867582A (zh) * 2018-03-14 2020-10-30 爱尔兰詹森科学公司 衣壳组装调节剂给药方案

Also Published As

Publication number Publication date
AU2020235442A1 (en) 2021-08-12
KR20210137484A (ko) 2021-11-17
EP3937928A1 (de) 2022-01-19
JP2022524819A (ja) 2022-05-10
CR20210481A (es) 2021-10-25
IL286209A (en) 2021-10-31
CN113557016A (zh) 2021-10-26
SG11202109710QA (en) 2021-10-28
CA3132095A1 (en) 2020-09-17
PE20212107A1 (es) 2021-11-04
ECSP21067052A (es) 2021-11-18
MX2021011030A (es) 2021-10-13
WO2020183020A1 (en) 2020-09-17
JOP20210250A1 (ar) 2023-01-30
BR112021017525A2 (pt) 2021-11-23

Similar Documents

Publication Publication Date Title
EP3897522A4 (de) Mikrokapselzusammensetzung
EP3877521A4 (de) Lipidnanopartikelformulierungen
IL287660A (en) Transmuted cycloalkyls as modulators of combined stress pathways
MA52019A (fr) Schéma posologique de modulateur d'assemblage de capside
EP3784707A4 (de) Stabile polyharnstoff-mikrokapsel-zusammensetzungen
EP3877522A4 (de) Lipidnanopartikelformulierungen
MA51903A (fr) Formulations d'anticorps b7-h4
EP3773721A4 (de) Stabile anti-cd79b-immunokonjugatformulierungen
MA54521A (fr) Dérivés d'oxopyridine substitués
MA53924A (fr) Modulateurs de l'expression d'apol1
EP3749309A4 (de) Hypertonische pharmazeutische zusammensetzungen mit einem anti-platin-chemoprotektor
MA55015A (fr) Formulations pharmaceutiques
ECSP21068097A (es) Anticuerpos claudina 6 y usos de los mismos
MA54052A (fr) Formulation d'anticorps
EP3828287A4 (de) Mci-diagnosemarker aufgrund von ad und anwendung davon
MA55280A (fr) Formulation solide de modulateur d'assemblage de capside
MA54139A (fr) Formulation d'anticorps
EP3824296A4 (de) Lebererkrankung
IL283450A (en) capsule formulations
EP4007590A4 (de) Dihydrohonokiol enthaltende formulierungen
EP3977855A4 (de) Stabile mikrobizide zusammensetzung
MA50570A (fr) Formulations de fulvestrant et méthodes d'utilisation de ces dernières
MA51645A (fr) Modulateurs de l'expression de dnm2
MA50547A (fr) Composés et compositions d'induction de la chondrogenèse
DK3801656T3 (da) Hudkompatibel silikonesammensætning